GlassScriptPhysician profile
Barry J Snyder
NPI 1104806470
$884.82
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $401 · 2020: $303 · 2021: $181.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $215.71 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $168.25 | 2019-2021 | |
| Amgen INC. | $123.45 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $90.53 | 2019-2021 | |
| Pfizer INC. | $66.48 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $44.27 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.01 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $26.08 | 2019 | |
| Lilly USA, LLC | $24.02 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $23.41 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $14.51 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.91 | 2021 | |
| Amarin Pharma, INC. | $11.59 | 2021 | |
| Daiichi Sankyo INC. | $11.40 | 2021 | |
| Dexcom, INC. | $11.20 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.